Posts by tag
clinical trial design
1 post
Combination immunotherapy with novel immune-oncology agents benefit NSCLC patients in presurgical setting
Patients with resectable non-small-cell lung cancer show improved major pathological response rates with combination immune oncology agents versus single-agent immunotherapy. The NeoCOAST trial, published in Cancer Discovery, 14 September, demonstrated that combining the anti-PD-L1 monoclonal antibody durvalumab with other novel…